Suzhou InnovaBio Pharmaceutical Technology Co., Ltd. (InnovaBio) has seen its STAR Market IPO application accepted by the Shanghai Stock Exchange on December 22, 2025, with Guotai Haitong Securities acting as the lead underwriter.
**Key Leadership Profiles** - **Qiang Jing**, Chairman (b.1982), holds 47.0448% voting rights as the ultimate controller. With a Ph.D. in Applied Economics from Tsinghua University, his career spans Citibank risk management and former MD roles at CICC Research before joining Xingze Capital in 2018. - **Yun Song**, Director, Board Secretary & CFO (b.1986), is a Tsinghua-trained chemical engineer with prior experience at CICC’s investment banking division and Xingze Investment.
**Company Overview** - **Established**: May 17, 2017 - **Registered Capital**: RMB 370.17 million - **Core Focus**: Addressing unmet clinical needs globally with a pipeline of 10 innovative drugs, including: - **XNW5004 (EZH2 inhibitor)**, **XNW27011 (Claudin 18.2 ADC)**, and **XNW28012 (TF ADC)** in Phase III trials for pancreatic/gastric cancers and lymphomas—all granted CDE Breakthrough Therapy Designation, with FDA Fast Track status for two. - **Imipenem/Cilastatin/Funobactam (XNW4107)**: NDA under review for Gram-negative bacterial pneumonia (HABP/VABP), with potential 2026 launch and FDA QIDP/FTD certifications.
**Financial & Strategic Highlights** - **BD Achievements**: Over $2B in cumulative licensing deals with partners like Astellas (全球制药Top 21), Everest Med (01952.HK), and Sinomab Bio (03681.HK), including $130M non-refundable upfront payment in 2025. - **R&D Expenditure**: Persistent losses (2022–2025 H1: RMB -4.63B cumulative), attributed to high R&D intensity. - **Risks**: No marketed products yet; profitability hinges on successful commercialization and BD continuity post-listing.
**Regulatory & Industry Recognition** - National "Little Giant" enterprise and Jiangsu Provincial Unicorn, with presentations at AACR, ASCO, and ESMO. - Adopts STAR Market’s 5th listing standard for pre-revenue biotech firms.
*Note: The company warns investors of prolonged unprofitability risks due to ongoing R&D investments.*